title: Clinical efficacy of low dose flutamide plus Diane-35 in the treatment of idiopathic hirsutism and polycystic ovary syndrome.
abstract: OBJECTIVE
  Idiopathic hirsutism (IH) or polycystic ovary syndrome (PCOS) are the most common causes of hirsutism which affects 5-10% of all women. The aim of this study was to evaluate the efficacy of flutamide plus diane 35 in the treatment of idiopathic hirsutism and polycystic ovary syndrome.
  
  
  METHODS
  26 polycystic ovary syndrome and 24 idiopathic hirsutism patients were evaluated. Fifty patients were divided into two groups according to their diagnosis: idiopathic hirsutism or polycystic ovary syndrome. All patients received 125 mg Flutamide once a day and Diane 35 tablets for 21 days of each month, for 12 months. We measured hirsutism scores and hormonal levels of all patients. Evaluations were done before treatment, in the 6th and 12th months of therapy.
  
  
  RESULTS
  There were no significant differences in Ferriman-Gallwey scores at the beginning and at the end of the therapy between the IH and PCOS groups. The decreases in Ferriman-Gallwey scores were significant in both groups in the 6th and 12th month of therapy. Combined treatment significantly decreased total and free testosterone, DHEAS and significantly increased SHBG levels in both groups and additionally decreased levels of LH, androstenodione and LH/FSH ratio in the polycystic ovary syndrome group.
  
  
  CONCLUSIONS
  Combined treatment was effective and safe in the treatment of hirsutism. Combined regimens have additional effects on the treatment of hirsutism.
authors.affiliation: Department of Obstetrics and Gynecology, Cumhuriyet University School of Medicine, Sivas, Turkey.
authors.forename: Abdullah
authors.initials: A
authors.lastname: Boztosun
authors.forename: Gökhan
authors.initials: G
authors.lastname: Açmaz
authors.forename: Ahmet
authors.initials: A
authors.lastname: Ozturk
authors.forename: Iptisam Ipek
authors.initials: II
authors.lastname: Müderris
mesh_terms: D000328:Adult; D000726:Androgen Antagonists / Q000008:administration & dosage*; D017373:Cyproterone Acetate / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D004997:Ethinyl Estradiol / Q000008:administration & dosage*; D005260:Female; D005485:Flutamide / Q000008:administration & dosage*; D006628:Hirsutism / Q000188:drug therapy*; D006801:Humans; D011085:Polycystic Ovary Syndrome / Q000188:drug therapy*; D012720:Severity of Illness Index; D016896:Treatment Outcome; D016387:Women's Health; D055815:Young Adult
chemical_list: D000726:Androgen Antagonists; D004338:Drug Combinations; D004997:Ethinyl Estradiol; D017373:Cyproterone Acetate; C032640:Cyproterone acetate, ethinyl estradiol drug combination; D005485:Flutamide